Healthcare -
Medical - Devices - NASDAQ - US
$ 2.52
0.8 %
$ 88.9 M
Market Cap
-4.94
P/E
1. INTRINSIC VALUE
Balance Sheet
Monogram Orthopaedics, Inc.
| Current Assets | 16.3 M |
| Cash & Short-Term Investments | 15.7 M |
| Receivables | 0 |
| Other Current Assets | 625 K |
| Non-Current Assets | 1.49 M |
| Long-Term Investments | 0 |
| PP&E | 338 K |
| Other Non-Current Assets | 1.15 M |
| Current Liabilities | 1.54 M |
| Accounts Payable | 1.17 M |
| Short-Term Debt | 138 K |
| Other Current Liabilities | 229 K |
| Non-Current Liabilities | 1.73 M |
| Long-Term Debt | 226 K |
| Other Non-Current Liabilities | 1.5 M |
EFFICIENCY
Earnings Waterfall
Monogram Orthopaedics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 15.3 M |
| Operating Income | -15.3 M |
| Other Expenses | 1.02 M |
| Net Income | -16.3 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Monogram Orthopaedics, Inc.
| Net Income | -16.3 M |
| Depreciation & Amortization | 430 K |
| Capital Expenditures | -84 K |
| Stock-Based Compensation | 1.17 M |
| Change in Working Capital | -839 K |
| Others | 1.68 M |
| Free Cash Flow | -14.1 M |
Wall Street Analysts Price Targets
Monogram Orthopaedics, Inc.
Wall Street analysts predict an average 1-year price target for MGRM of $5.4 , with forecasts ranging from
a
low of
$5.4 to a high of $5.4 .
MGRM Lowest Price Target
Wall Street Target
5.4 USD
114.29%
MGRM Average Price Target
Wall Street Target
5.4 USD
114.29%
MGRM Highest Price Target
Wall Street Target
5.4 USD
114.29%
4. DIVIDEND
ANALYSIS
MGRM does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Monogram Orthopaedics, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Monogram Technologies Partners with Urvin to Launch an Exclusive, Verified Shareholder Community
AUSTIN, TX / ACCESS Newswire / March 20, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, is pleased to announce its partnership with Urvin, a private, verified message board exclusively for active Monogram shareholders. This platform offers a way for shareholders to communicate directly with each other while providing Monogram with an additional tool to provide important company updates and reach the broadest possible shareholder audience.
accessnewswire.com
- 1 month ago
Monogram Technologies Announces FDA 510(k) Clearance for the Monogram mBôsTM TKA System
Monogram May Market the Monogram mBôs™ TKA System, Subject to the Requirements of the Federal Food, Drug, and Cosmetic Act (the Act). The Company is Preparing for Commercialization and Evaluating Strategies to Support the Adoption of its Robotic-Assisted Technology AUSTIN, TX / ACCESS Newswire / March 17, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its Monogram mBôs™ TKA System.
accessnewswire.com
- 1 month ago
Monogram Technologies Inc. (MGRM) Q4 2024 Earnings Call Transcript
Monogram Technologies Inc. (NASDAQ:MGRM ) Q4 2024 Earnings Conference Call March 11, 2025 4:30 PM ET Company Participants Larry Holub - Investor Relations Benjamin Sexson - Chief Executive Officer Noel Knape - Chief Financial Officer Conference Call Participants Jason Wittes - ROTH MKM Tom Kerr - Zacks Small-Cap Research Larry Holub Good afternoon everyone. I'm Larry Holub, Director at MZ North America, and would like to welcome you to the Monogram Technologies fourth quarter and full year 2024 financial results and business update conference call.
seekingalpha.com
- 1 month ago
CORRECTION: Monogram Technologies Reports Full Year 2024 Financial Results
This Press Release is Acting as a Correction to the Financial Tables in the Previous Release Completed all Supplemental Testing and has Submitted its Formal Response to the FDA's Additional Information Request (AIR) Management to Host Business Update Conference Call on Wednesday, March 12, 2025, at 4:30 p.m. Eastern Time AUSTIN, TEXAS / ACCESS Newswire / March 12, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, has reported its financial and operational results for the fourth quarter and year ended December 31, 2024.
accessnewswire.com
- 1 month ago
Monogram Technologies Reports Full Year 2024 Financial Results
Completed all Supplemental Testing and has Submitted its Formal Response to the FDA's Additional Information Request (AIR) Management to Host Business Update Conference Call on Wednesday, March 12, 2025, at 4:30 p.m. Eastern Time AUSTIN, TX / ACCESS Newswire / March 12, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, has reported its financial and operational results for the fourth quarter and year ended December 31, 2024.
accessnewswire.com
- 1 month ago
Monogram Technologies to Participate in the 37th Annual ROTH Conference in California March 16-18, 2025
AUSTIN, TX / ACCESS Newswire / March 5, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced that Chief Executive Officer Ben Sexson and Chief Financial Officer Noel Knape will participate in the 37th Annual ROTH Conference at the Laguna Cliffs Marriott Resort & Spa in Dana Point, CA March 16-18, 2025. Mr. Sexson and Mr.
accessnewswire.com
- 1 month ago
Monogram Technologies to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday, March 12, 2025 at 4:30 p.m. Eastern Time
AUSTIN, TX / ACCESS Newswire / February 27, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, will hold a conference call webcast on Wednesday, March 12, 2025 at 4:30 p.m. Eastern Time in conjunction with its reported financial results for the fourth quarter and full fiscal year ended December 31, 2024, and to discuss regulatory updates and key milestones.
accessnewswire.com
- 1 month ago
Monogram Technologies Provides Regulatory Update on mBôs TKA System and Clinical Trial Preparation in India
Company has Completed all Supplemental Testing and has Submitted its Formal Response to the FDA's Additional Information Request (AIR) Investigator Meeting and Clinical Trial Training Held at the Shalby Hospital in Ahmedabad, India AUSTIN, TX / ACCESS Newswire / February 26, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today provided an update regarding its 510(k) premarket filing submission to the U.S. Food and Drug Administration ("FDA") for the Company's mBôs TKA System. The Company has completed all supplemental testing and submitted its formal response to the U.S. Food and Drug Administration (FDA) regarding the Additional Information Request (AIR) received on September 30, 2024.
accessnewswire.com
- 1 month ago
Monogram Technologies Provides 510(k) Submission Update Following Positive Meeting with FDA
Management Anticipates That it has Sufficiently Addressed the FDA's Concerns to Mitigate the Need for a Clinical Data Request Management Anticipates a Comprehensive AIR Response in Q1 2025 AUSTIN, TX / ACCESSWIRE / December 18, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today provided an update from its Submission Issue Request (SIR) meeting with the U.S. Food and Drug Administration ("FDA") on December 17, 2024, regarding its 510(k) premarket filing submission for the Company's mBôs TKA System (the "Application"). The Application was submitted on July 19, 2024, and passed the initial FDA Administrative Review.
accesswire.com
- 4 months ago
Monogram Technologies Inc. (MGRM) Q3 2024 Earnings Call Transcript
Monogram Technologies Inc. (NASDAQ:MGRM ) Q3 2024 Earnings Call Transcript November 19, 2024 4:30 PM ET Company Participants Ben Sexson - CEO Noel Knape - CFO Larry Holub - IR Conference Call Participants Tom Kerr - Zacks Investment Research Operator Greetings and welcome to the Monogram Technologies Third Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.
seekingalpha.com
- 5 months ago
Monogram Technologies Reports Third Quarter 2024 Financial Results
Closed an Upsized and Oversubscribed $13 Million Public Offering to Fund Near-term Commercialization Milestones Management to Host Business Update Conference Call on Tuesday, November 19, 2024 at 4:30 p.m. Eastern Time AUSTIN, TX / ACCESSWIRE / November 14, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, has reported its financial and operational results for the third quarter ended September 30, 2024.
accesswire.com
- 5 months ago
Monogram Technologies to Host Third Quarter 2024 Results Conference Call on Tuesday, November 19, 2024 at 4:30 p.m. Eastern Time
AUSTIN, TX / ACCESSWIRE / November 12, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, will hold a conference call on Tuesday, November 19, 2024 at 4:30 p.m. Eastern Time in conjunction with its reported financial results for the third quarter ended September 30, 2024 and to discuss key milestones.
accesswire.com
- 5 months ago
8. Profile
Summary
Monogram Orthopaedics, Inc. MGRM
COUNTRY
US
INDUSTRY
Medical - Devices
MARKET CAP
$ 88.9 M
Dividend Yield
0.00%
Description
Monogram Orthopaedics, Inc. focuses on developing a product solution architecture to enable mass personalized optimization of orthopedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. Its robot prototype executes optimized paths for high-precision insertion of optimized implants in synthetic bone specimens. The company was formerly known as Monogram Arthroplasty Inc. and changed its name to Monogram Orthopaedics, Inc. in March 2017. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Contact
3913 Todd Lane, Austin, TX, 78744
https://www.monogramorthopedics.com
IPO
Date
May 18, 2023
Employees
27
Officers
Chris Tyson
Executive Vice President - MZ North America
Mr. Noel Knape CPA, M.B.A.
Chief Financial Officer
Dr. Kamran Shamaei Ph.D.
Chief Technology Officer
Dr. Douglas Unis
Founder, Chief Medical Officer & Director
Mr. Benjamin Sexson C.F.A.
Chairman of the Board, President & Chief Executive Officer